Nutrition and Cancer-An International Journal最新文献

{"title":"Isoquercitrin Inhibits Lung Cancer Cell Growth Through Triggering Pyroptosis and Ferroptosis.","authors":"Haiyin Fan, Pengfei Xu, Bin Zou, Huanyuan Wang, Chao Li, Jian Huang","doi":"10.1080/01635581.2024.2416246","DOIUrl":"10.1080/01635581.2024.2416246","url":null,"abstract":"<p><p>Isoquercitrin possesses anti-tumor activity in several types of cancers, however, its effects and underlying mechanisms on lung cancer have not been reported. Human lung cancer cell lines as well as normal lung epithelial BEAS-2B cells were treated with isoquercitrin. The influences of isoquercitrin <i>in vitro</i> were evaluated by determining cell viability, apoptosis, pyroptosis, and ferroptosis. Additionally, A549 tumor-bearing mice were generated to explore the anti-cancer effect of isoquercitrin <i>in vivo</i>. We found that isoquercitrin dose-dependently reduced lung cancer cells' viability, with no toxicity against BEAS-2B cells. Isoquercitrin at 40 μM and 80 μM was used <i>in vitro</i>. Isoquercitrin increased apoptosis, elevated NLRP3 inflammasome activation-mediated pyroptosis, and promoted ferroptosis in lung cancer cells. NLRP3 knockdown and caspase-1 selective inhibitor VX-765 attenuated isoquercitrin-induced pyroptosis and ferroptosis, but not apoptosis. Furthermore, isoquercitrin accelerated ROS generation, while ROS inhibitor N-acetylcysteine abrogated isoquercitrin-induced apoptosis, NLRP3 related-pyroptosis and ferroptosis. <i>In vivo</i>, isoquercitrin (1 mg/kg and 5 mg/kg) inhibited tumor growth, increased apoptosis, NLRP3-related pyroptosis, ferroptosis and ROS generation in tumors. Taken together, isoquercitrin inhibits lung cancer growth by triggering ROS/NLRP3-mediated pyroptosis and ferroptosis, with ROS also directly inducing apoptosis. This suggests that isoquercitrin might be a potential therapeutic agent for lung cancer.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"299-310"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Sarcopenia, Clinical Outcomes, and Survival in Patients with Extensive-Stage Small Cell Lung Cancer Treated with First-Line Immunochemotherapy: A Prospective Cohort Study.","authors":"Le Tian, Jia-Xin Huang, Rui Wan, Jie Zhang, Xi Zhang, Ning Li, Na Li, Xin-Qi Liu, Chen-Xin Song, Xin-Yi Wang, Lei Yu, Shao-Ming Wang, Zhi-Jie Wang, Ming-Hua Cong","doi":"10.1080/01635581.2024.2392297","DOIUrl":"10.1080/01635581.2024.2392297","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the association between sarcopenia, short-term efficacy, and long-term survival in patients with extensive small-cell lung cancer (SCLC) treated with standard first-line immunochemotherapy.</p><p><strong>Methods: </strong>A total of 63 patients initially diagnosed with extensive-stage small cell lung cancer were enrolled in the prospective study from December 1, 2020 to December 31, 2022. The clinical characteristics, body composition, blood test results, and image data were obtained before treatment. Patients were divided into sarcopenia and non-sarcopenia groups according to the diagnostic criteria of the Asian Sarcopenia Working Group 2019. The primary outcome was overall survival (OS) and comprehensive survival analyses were performed. Secondary outcomes included short-term efficacy and adverse events associated with first-line immunochemotherapy.</p><p><strong>Results: </strong>The median age of the 63 patients enrolled in our study was 63.0 years (40-80 years). The incidence of sarcopenia was 19.0% (12/63) in patients with extensive SCLC. Compared with non-sarcopenia patients, extensive-stage SCLC patients with sarcopenia were significantly older (69.0 vs. 62.0, <i>P</i> = 0.017), and had lower body mass index (BMI) (20.29 vs. 24.27, <i>P</i> < 0.001), hand grip strength (HGS) (20.42 vs. 30.75, <i>P</i> < 0.001), and albumin (35.9 vs. 41.40, <i>P</i> < 0.001). The objective response rate after two cycles of standard first-line immunochemotherapy in the sarcopenia group was lower than in the non-sarcopenia group (30.0 vs. 78.9%, <i>P</i> = 0.012). There was no significant difference in chemotherapy-related hematological toxicity between the two groups. During a median follow-up of 15 months (3-33 months), patients with extensive SCLC had a median OS of 24 months, with 1-year survival of 75% and 2-year survival of 52%, respectively. Compared to non-sarcopenia patients, the median OS in the sarcopenia group was significantly shorter (9 vs. 24 months, <i>P</i> = 0.0014). Multivariate Cox analysis showed that sarcopenia was an independent risk factor for OS in patients with extensive SCLC (HR = 4.993, 95%CI = 1.106-22.538, <i>P</i> = 0.037).</p><p><strong>Conclusions: </strong>Patients with Extensive SCLC and sarcopenia had worse clinical outcomes and shorter OS. Sarcopenia is a prognostic factor affecting first-line treatment efficacy and long-term survival of patients with SCLC in the era of immunotherapy.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"62-69"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142005956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Chemopreventive Impact of Diet-Derived Phytochemicals on the Adipose Tissue and Breast Tumor Microenvironment Secretome.","authors":"Naoufal Akla, Carolane Veilleux, Borhane Annabi","doi":"10.1080/01635581.2024.2401647","DOIUrl":"10.1080/01635581.2024.2401647","url":null,"abstract":"<p><p>Cancer cells-derived extracellular vesicles can trigger the transformation of adipose-derived mesenchymal stem cells (ADMSC) into a pro-inflammatory, cancer-associated adipocyte (CAA) phenotype. Such secretome-mediated crosstalk between the adipose tissue and the tumor microenvironment (TME) therefore impacts tumor progression and metastatic processes. In addition, emerging roles of diet-derived phytochemicals, especially epigallocatechin-3-gallate (EGCG) among other polyphenols, in modulating exosome-mediated metabolic and inflammatory signaling pathways have been highlighted. Here, we discuss how selected diet-derived phytochemicals could alter the secretome signature as well as the crosstalk dynamics between the adipose tissue and the TME, with a focus on breast cancer. Their broader implication in the chemoprevention of obesity-related cancers is also discussed.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"9-25"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diet Quality in Patients with Breast Cancer: Results of a Single Cohort Study in a Midwestern US Population.","authors":"Birgit Khandalavala, Sarah Carlson, Lina Elsayed, Jenenne Geske, Jairam Krishnamurthy","doi":"10.1080/01635581.2024.2433812","DOIUrl":"10.1080/01635581.2024.2433812","url":null,"abstract":"<p><p>Emerging research underscores the relationship between diet quality in patients with breast cancer and their cardiovascular health. This study examines the role of diet quality in patients post-breast cancer diagnosis in a single cohort in the midwestern United States (US), along with barriers to the adoption of a healthy diet and willingness to change diet. This cross-sectional study surveyed 108 patients with breast cancer. Diet quality was assessed using the Rapid Assessment of Eating in Participants - Shortened version (REAP-S). Participants had an average total REAP-S Score of 28.44 on a scale of 13-39. This score is lower than that of the average omnivorous population of the US and remained so as time since diagnosis progressed despite participants' overwhelming willingness to make changes toward a better quality diet. Several key barriers to healthier eating were identified, including unpredictable schedules and time constraints. Subaverage diet quality scores suggest that breast cancer patients elevate their future risk of adverse cardiovascular health and underscores the necessity for targeting interventions and reducing barriers to enhance diet quality.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"380-388"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Digestive Cancer Risk Score Based on Nutritional Predictors: A Risk Prediction Model in the Golestan Cohort Study.","authors":"Masoumeh Jabbari, Meisam Barati, Ali Kalhori, Hassan Eini-Zinab, Farid Zayeri, Hossein Poustchi, Akram Pourshams, Azita Hekmatdoost, Reza Malekzadeh","doi":"10.1080/01635581.2025.2474264","DOIUrl":"10.1080/01635581.2025.2474264","url":null,"abstract":"<p><p>This study aimed to develop a non-laboratory simple and useful scoring system to predict risk of incident digestive cancers within the healthcare and clinical framework in Iranian population. The present study was conducted on the collected data from the Golestan Cohort Study. A total of 49,173 participants, aged 37-80 years, were recruited from Gonbad City and 326 rural villages and were followed from 2004 to 2021 in Iran. A non-laboratory model for prediction of the 15-year risk of digestive cancers by means of dietary predictors and formulating a simple and useful scoring system in Iranian population was done in this study. A total of 43550 participants (25249 women and 18301 men) were included in the final analysis. The model's discrimination and calibration were assessed by concordance statistic (C-statistic) and calibration plot, respectively. The model had an acceptable discrimination in both derivation (C-statistic: 0.76) and validation (C-statistic: 0.70) samples (<i>p</i> < 0.001). Also, the calibration of model in derivation and validation datasets was 0.88 and 0.91, respectively. As an assessment tool, the established simple and practical nutritional risk score is suitable for motivating at-risk individuals to change lifestyles and dietary patterns to reduce future risks and prevent health problems.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"518-529"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Oral Nutrition Supplementation and Dietary Education on Nutritional Status, Knowledge, Attitudes, and Behaviour in Cancer Patients: A Randomized Clinical Trial.","authors":"Elisna Syahruddin, Tri Apriliawan Bendarto Rahardjo, Oni Khonsa, Anindhita, Galoeh Adyasiwi, Luh Eka Purwani, Anova Fatimah, Sri Anita Putri Simanulang","doi":"10.1080/01635581.2025.2474260","DOIUrl":"10.1080/01635581.2025.2474260","url":null,"abstract":"<p><p>Cancer patients often experience significant weight loss due to metabolic changes, increased resting energy expenditure (REE), and poor nutrient intake, particularly exacerbated by treatments like chemotherapy and radiation. This study aimed to determine whether combining Oral Nutrition Supplements (ONS) with dietary education is more effective than dietary education alone in improving nutritional outcomes for cancer patients. An open-label randomized clinical trial at Persahabatan Hospital in Jakarta, Indonesia, involved 108 patients with lung or gynecological cancer, with 87 completing the study. Participants were assigned to receive either dietary education plus ONS (intervention group) or dietary education alone (control group). Results indicated that while both groups improved their nutrition knowledge, the intervention group experienced significant increases in body weight (1.68 ± 3.96 kg) and body mass index (BMI) (0.86 ± 1.96 kg/m²), whereas the control group lost weight. Additionally, the intervention group had a lower rate of anemia (60% vs. 80.9%), though no significant differences were found in albumin levels or inflammation status. These findings suggest that ONS combined with dietary education may help improve weight and BMI in cancer patients, warranting further research to confirm these benefits and assess long-term effects.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"474-482"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diet as an Adjunct Therapy in Reducing Chemotherapy Toxicities and Improving Patients Quality of Life: A Systematic Review and Meta-Analysis.","authors":"Jessica Abene, Sherilyn Tyburski, Tanja V E Kral, Ryan Quinn, Jie Deng","doi":"10.1080/01635581.2024.2437833","DOIUrl":"10.1080/01635581.2024.2437833","url":null,"abstract":"<p><p>This review analyzed existing literature regarding the relationship between different diets and chemotherapy toxicities, as well as the quality of life (QOL) among patients undergoing treatment. It aims to identify the most advantageous diet for cancer patients. PubMed, CINAHL, and Embase were used to select randomized control trials (RCTs) assessing the relationship between a specific diet and chemotherapy toxicities and/or QOL in patients as of October 2023. Out of 1,419 records, 11 RCTs were included. Analyses were stratified by diet type. Pooled odds ratios and 95% confidence intervals (CI) were obtained from the random-effect model using STATA. We included 7 studies testing fasting variations; 1 testing a ketogenic diet; 1 testing a Mediterranean diet; 1 testing a plant-based, high-protein diet; and 1 testing an anti-inflammatory diet. Four fasting studies were in the meta-analysis. The random-effects meta-analysis showed no significant difference in the incidence of chemotherapy toxicities between fasting and non-fasting patients. There is insufficient evidence to determine which dietary intervention is the most advantageous, however, there is evidence that all the diets examined may complement conventional cancer therapy by helping to reduce chemotherapy toxicities. No intervention can be ruled out. More research is needed in this field.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"341-359"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prevalence and Prognostic Impact of Cancer Cachexia on Overall Survival in Patients with Gastrointestinal Cancer: A Meta-Analysis.","authors":"Heng Zhang, Yueshi Zhang, Xuan Tang, Shiqi Zhang, Changfeng Man, Dandan Gong, Yu Fan","doi":"10.1080/01635581.2025.2492126","DOIUrl":"10.1080/01635581.2025.2492126","url":null,"abstract":"<p><p>Cancer cachexia is a multifactorial syndrome characterized by progressive weight loss, predominantly due to the depletion of skeletal muscle mass and adipose tissue. This meta-analysis aimed to evaluate the prognostic impact of cancer cachexia on overall survival in patients with gastrointestinal cancers. Two independent investigators conducted a systematic literature search across PubMed, Embase, and Web of Science. Eligible studies included cohort studies and post hoc analyses of clinical trials that examined the association between cancer cachexia and overall survival in gastrointestinal cancer patients. A total of 22 studies involving 10,480 patients were included in the analysis. The pooled prevalence of cachexia among gastrointestinal cancer patients was 50% (95% confidence interval [CI] 41-59). Meta-analysis demonstrated that cancer cachexia was significantly associated with reduced overall survival (hazard ratio [HR] 1.50; 95% CI 1.35-1.68). Subgroup analyses further confirmed that cancer cachexia remained a robust predictor of poorer survival, irrespective of study design, gastrointestinal cancer subtype, patients' age, country of origin, tumor stage, cachexia definition, or follow-up duration. These findings indicate that cancer cachexia is highly prevalent among gastrointestinal cancer patients and serves as a significant independent predictor of shortened overall survival.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"590-599"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activation of the WNT7B/β-Catenin Pathway Initiates <i>GLUT1</i> Expression and Promotes Aerobic Glycolysis in Colorectal Cancer Cells.","authors":"Fan Jiang, Zhiju Chen, Xiang Wang, Chuangyu Huang, Yiwei Li, Ning Liu","doi":"10.1080/01635581.2024.2418607","DOIUrl":"10.1080/01635581.2024.2418607","url":null,"abstract":"<p><p>Glucose is an important energy source for tumors, however the molecular mechanisms by which tumor cells regulate glucose uptake remain unclear. In this study, we aimed to investigate the regulation mechanism of the WNT7B/β-catenin pathway for glucose transporter 1 (GLUT1)-mediated glucose metabolism in colorectal cancer. Here, we found that WNT7B expression levels were significantly increased in colorectal cancer tissues and closely associated with the clinical stage and lymph node metastasis in patients with colorectal cancer. Next, we confirmed that WNT7B significantly increased the glucose consumption and lactic acid levels in SW480 cells by overexpressing WNT7B. Additionally, gene and protein levels of GLUT1 were increased in WNT7B-overexpressing SW480 cells. However, WNT7B knockdown reversed these effects. WNT7B also enhanced GLUT1-mediated cell proliferation, invasion, and migration. WNT7B overexpression inhibited the effect of glucose deprivation on apoptosis. The WNT/β-catenin signaling pathway inhibitor, LGK974, inhibited WNT7B secretion, leading to GLUT1 levels downregulation and promotion of cell apoptosis. Ectopic tumor xenograft model experiments revealed that WNT7B promoted tumor progression in mice. Overall, our results suggest that WNT7B promotes β-catenin entry into the nucleus to initiates GLUT1 transcription, increases glucose transport and consumption, and enhances aerobic glycolysis, thus promoting tumor progression in colorectal cancer cells.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"311-323"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coconut Milk Consumption and Breast Cancer Risk in Thai Women: A Case-Control Study.","authors":"Phornsawan Leechanavanicpan, Pakkapong Phucharoenrak, Phenphop Phansuea, Dunyaporn Trachootham","doi":"10.1080/01635581.2024.2390202","DOIUrl":"10.1080/01635581.2024.2390202","url":null,"abstract":"<p><p>Coconut milk contains plant-based saturated fat and phytochemicals with antioxidant activities. However, its role in breast cancer risk remains unclear. A case-control study was conducted on 244 participants to study the association. The Case group includes 61 newly diagnosed breast cancer patients receiving < 6 months of therapies. The Control group includes 183 healthy people with matched characteristics. A new questionnaire was developed, validated, and used in this study to estimate the frequency of coconut milk-containing food intake. Results show that the questionnaire has satisfactory content validity, test-retest reliability, and criterion-related validity. From the case-control study, either consuming 1-3 or 4-6 times/week of coconut-milk-containing curry or consuming 4-6 times/week of coconut milk-topped desserts are associated with increased risk of breast cancer (OR = 5.23, 5.6, and 2.6 respectively, <i>p</i> < 0.01). Consuming less than half of coconut milk liquid in desserts correlated with a reduced risk (OR = 0.43, <i>p</i> < 0.05). The findings suggest that moderate (less than half of a serving) and infrequent (less than once a week) consumption of coconut milk may be beneficial for breast cancer prevention. A larger scale study is warranted to confirm the findings and provide evidence for dietary recommendations.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"51-61"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}